Ro 41-0960
Based on 1 Customer Validation
Ro 41-0960 is a CNS-penetrant, orally active catechol-O-methyl transferase (COMT) inhibitor. Ro 41-0960 reduces dopamine catabolism, increases striatal dopamine and DOPAC levels, decreases striatal HVA levels, induces apoptosis, inhibits proliferation and extracellular matrix formation in uterine fibroid cells. Ro 41-0960 arrests or shrinks uterine fibroid lesions in rats. Ro 41-0960 can be used for the research of Parkinson’s disease, uterine leiomyomas, and breast cancer.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 98.22%
- CAS No.: 125628-97-9
- Formule: C13H8FNO5
- Masse moléculaire:277.20
-
Stockage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
Apoptosis Compound Library
HY-L003
-
Metabolism/Protease Compound Library
HY-L012
-
Neuronal Signaling Compound Library
HY-L013
-
Anti-Cancer Compound Library
HY-L025
-
CNS-Penetrant Compound Library
HY-L028
-
Orally Active Compound Library
HY-L061
-
Anti-Breast Cancer Compound Library
HY-L074
-
Anti-Parkinson's Disease Compound Library
HY-L085
-
Neurodegenerative Disease-related Compound Library
HY-L086
-
Human Metabolite Library
HY-L123
-
Metabolic Enzyme Compound Library
HY-L146
-
Cell Death Library
HY-L162
-
Bioactive Compound Library Max
HY-L181
-
Bioactive Compound Library
HY-L001
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
-
Mass Spectrometry Human Metabolite Library
HY-L215
Activité biologique
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HT-29 | EC50 |
8.66 μM
Compound: Ro41-0960
|
Agonist activity at GPR35 in human HT-29 cells assessed as induction of whole cell dynamic mass redistribution after 50 mins by resonant waveguide grating biosensor analysis
Agonist activity at GPR35 in human HT-29 cells assessed as induction of whole cell dynamic mass redistribution after 50 mins by resonant waveguide grating biosensor analysis
|
10.1039/C2MD20210G |
| U2OS | EC50 |
54.4 μM
Compound: Ro41-0960
|
Agonist activity at GPR35 in human U2OS cells assessed as induction of beta-arrestin translocation after 5 hrs by beta-lactamase reporter gene assay
Agonist activity at GPR35 in human U2OS cells assessed as induction of beta-arrestin translocation after 5 hrs by beta-lactamase reporter gene assay
|
10.1039/C2MD20210G |
Ro 41-0960 (0.05-50 µM; 20 min) directly activates SERCA2a in pig cardiac sarcoplasmic reticulum microsomes with an EC50 of 27 µM and increases ATPase turnover by 38%[3].
Ro 41-0960 (0.5-100 µM; 30 min) exerts concentration-dependent, contrasting marginal effects on Ca2+ transient amplitude and CaTD50, and minimal effects on beat rate, in human iPSC-derived cardiomyocytes[3].
Ro 41-0960 inhibits rat brain COMT with an IC50 of 16 nmol/L and rat liver COMT with an IC50 of 42 nmol/L[4].
Ro 41-0960 (30 min) potently inhibits COMT activity in cytosolic fractions from healthy human mammary tissues, with IC50 values ranging from 5.1 nM to 42.1 nM across 7 individual tissue samples, and fully blocks activity at 0.3 μM[5].
Ro 41-0960 (10 μM; 5-6 h) inhibits COMT activity in MCF-7 human mammary tumor cells by ~98%, reducing catechol estrogen inactivation and increasing catechol estrogen-induced DNA damage by ~200% without causing cytotoxicity[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Ro 41-0960 (150 mg/kg; s.c.; twice daily; 28 days) arrests growth or shrinks uterine fibroids in Eker rats[2].
Ro 41-0960 (30 mg/kg; i.p.; single dose) attenuates or completely prevents L-Dopa (HY-N0304)-induced changes in sulfur amino acid metabolite concentrations in rat brain regions, peripheral tissues, and plasma, while having minimal effects on these metabolites when administered alone[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Wistar rats (male, 270-320 g)[1]
-
Dosage:20 mg/kg
-
Administration:i.p.; single dose (acute); daily; 5 days (chronic)
-
Result:Produced a statistically significant 123.6% increase in striatal DA content, a 234.6% increase in striatal DOPAC content, and a 58.0% reduction in striatal HVA content relative to saline controls (acute treatment).
Produced a 122.5% increase in striatal DA content, a 225.5% increase in striatal DOPAC content, and a 13.1% reduction in striatal HVA content relative to saline controls (chronic treatment).
Caused a significantly greater reduction in HVA content compared to the acute treatment.
-
Animal Model:Eker rats (female, 14-16 months old, germline mutation in tuberous sclerosis-2 tumor suppressor gene)[2]
-
Dosage:150 mg/kg
-
Administration:s.c.; twice daily; 28 days
-
Result:Exhibited fibroid volumes of 86% and 105% of initial burden at 2 and 4 weeks post-treatment, respectively.
Increased the urinary 2-hydroxy E2/16-hydroxy E2 ratio.
Increased p53 mRNA levels.
Decreased PARP1-positive cells.
Decreased PCNA-positive cells.
Decreased cyclin D1-positive cells.
Decreased TGFb3 mRNA levels.
Did not alter normal tissue histology, serum liver enzyme levels (AST, ALT, total bilirubin), or urinary DPD levels.
-
Animal Model:Sprague-Dawley rats (male, ~200 g)[4]
-
Dosage:30 mg/kg
-
Administration:i.p.; single dose
-
Result:Showed no significant difference in mean SAM and SAH concentrations in cortex, hippocampus, cerebellum, spleen, kidney, and liver.
Increased mean striatal SAM concentration.
Decreased mean striatal SAH concentration.
Showed no significant difference in mean total plasma homocysteine concentration.
Increased mean SAM concentrations significantly in cortex, hippocampus, cerebellum, striatum, spleen, and kidney.
Chemical Information
-
CAS No. 125628-97-9
-
Appearance Solid
-
Masse moléculaire 277.20
-
Formule C13H8FNO5
-
Color Light yellow to yellow
-
SMILES
O=C(C1=CC([N+]([O-])=O)=C(C(O)=C1)O)C2=CC=CC=C2F
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Solvant et solubilité
DMSO : ≥ 100 mg/mL (360.75 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (9.02 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (9.02 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (282 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Instruction de manipulation (2659 KB)
Références
[2]. Hassan MH, et al. Towards non-surgical therapy for uterine fibroids: catechol-O-methyl transferase inhibitor shrinks uterine fibroid lesions in the Eker rat model. Hum Reprod. 2011;26(11):3008-3018. [Content Brief]
[3]. Aguayo-Ortiz R, et al. A multiscale approach for bridging the gap between potency, efficacy, and safety of small molecules directed at membrane proteins. Sci Rep. 2021 Aug 16;11(1):16580. [Content Brief]
[4]. Miller JW, et al. Effect of L-Dopa and the catechol-O-methyltransferase inhibitor Ro 41-0960 on sulfur amino acid metabolites in rats. Clin Neuropharmacol. 1997 Feb;20(1):55-66. [Content Brief]
[5]. van Duursen MB, et al. Phytochemicals inhibit catechol-O-methyltransferase activity in cytosolic fractions from healthy human mammary tissues: implications for catechol estrogen-induced DNA damage. Toxicol Sci. 2004;81(2):316-324. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.6075 mL | 18.0375 mL | 36.0750 mL | 90.1876 mL |
| 5 mM | 0.7215 mL | 3.6075 mL | 7.2150 mL | 18.0375 mL | |
| 10 mM | 0.3608 mL | 1.8038 mL | 3.6075 mL | 9.0188 mL | |
| 15 mM | 0.2405 mL | 1.2025 mL | 2.4050 mL | 6.0125 mL | |
| 20 mM | 0.1804 mL | 0.9019 mL | 1.8038 mL | 4.5094 mL | |
| 25 mM | 0.1443 mL | 0.7215 mL | 1.4430 mL | 3.6075 mL | |
| 30 mM | 0.1203 mL | 0.6013 mL | 1.2025 mL | 3.0063 mL | |
| 40 mM | 0.0902 mL | 0.4509 mL | 0.9019 mL | 2.2547 mL | |
| 50 mM | 0.0722 mL | 0.3608 mL | 0.7215 mL | 1.8038 mL | |
| 60 mM | 0.0601 mL | 0.3006 mL | 0.6013 mL | 1.5031 mL | |
| 80 mM | 0.0451 mL | 0.2255 mL | 0.4509 mL | 1.1273 mL | |
| 100 mM | 0.0361 mL | 0.1804 mL | 0.3608 mL | 0.9019 mL |
Ro 41-0960 Related Classifications
HY-125339 Related Classifications
Powered by Bioz